Literature DB >> 2005112

Processing of the p62 envelope precursor protein of Semliki Forest virus.

S K Jain1, S DeCandido, M Kielian.   

Abstract

The spike protein of Semliki Forest virus is composed of three subunits, E1, E2, and E3, which mediate the fusion of the virus membrane with that of the host cell. E2 and E3 are synthesized as a precursor, p62, which is cleaved post-translationally after an Arg-His-Arg-Arg sequence. In vitro mutagenesis of a cDNA clone of the spike proteins was used to specifically alter amino acids in this cleavage site. Cleavage of p62 was completely blocked by mutation of the proximal Arg residue to Phe, without affecting transport or surface expression of the spike protein. The cleavage mutation resulted in the loss of spike protein fusion activity within the physiological pH range. Fusion activity was restored by cleavage with exogenous chymotrypsin and showed the same low pH dependence as that of wild type. The cleavage sensitivity of newly synthesized p62 was investigated by pulse-chase analysis and chymotrypsin treatment in detergent solution. p62 was sensitive to cleavage immediately following its synthesis. Protein trapped in the rough endoplasmic reticulum or Golgi apparatus by carbonyl cyanide m-chlorophenylhydrazone, monensin, or Brefeldin A treatment was also fully sensitive to cleavage. These results suggest that p62 does not require an organelle-mediated conformational change for processing. Thus, in vivo, the site of p62 processing is probably controlled by the location or activity of the cleavage enzyme, rather than the sensitivity of the p62 substrate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2005112

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Formation and characterization of the trimeric form of the fusion protein of Semliki Forest Virus.

Authors:  D L Gibbons; A Ahn; P K Chatterjee; M Kielian
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Mutagenesis of the putative fusion domain of the Semliki Forest virus spike protein.

Authors:  P Levy-Mintz; M Kielian
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  The role of E3 in pH protection during alphavirus assembly and exit.

Authors:  Onyinyechukwu Uchime; Whitney Fields; Margaret Kielian
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

4.  Changing the protease specificity for activation of a flavivirus, tick-borne encephalitis virus.

Authors:  Wolfgang Fischl; Sigrid Elshuber; Sabrina Schrauf; Christian W Mandl
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

5.  The dynamic envelope of a fusion class II virus. E3 domain of glycoprotein E2 precursor in Semliki Forest virus provides a unique contact with the fusion protein E1.

Authors:  Shang-Rung Wu; Lars Haag; Mathilda Sjöberg; Henrik Garoff; Lena Hammar
Journal:  J Biol Chem       Date:  2008-07-02       Impact factor: 5.157

6.  fus-1, a pH shift mutant of Semliki Forest virus, acts by altering spike subunit interactions via a mutation in the E2 subunit.

Authors:  S Glomb-Reinmund; M Kielian
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Suppressors of cleavage-site mutations in the p62 envelope protein of Semliki Forest virus reveal dynamics in spike structure and function.

Authors:  I Tubulekas; P Liljeström
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  The alphavirus E3 glycoprotein functions in a clade-specific manner.

Authors:  Anthony J Snyder; Suchetana Mukhopadhyay
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Resuscitating mutations in a furin cleavage-deficient mutant of the flavivirus tick-borne encephalitis virus.

Authors:  Sigrid Elshuber; Christian W Mandl
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 10.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.